Monday, April 09, 2018 11:30:33 AM
It benefits them to get their stock out of being oversold so they have more options, should new opportunities arise on the acquisition side, and while dilution will be a constant until they monetize something from their portfolio, it's certainly not the norm for biotechs to receive zero to negative value for their products (if they're presumed to eventually be very profitable -- and one presumes a women's Viagra cream will garner some interest out there).
I have 31000 shares, for now, and while I likely won't go much higher than that, I simply don't understand how $DARE won't command a $100 million MC once there's some understanding of the good products in its portfolio. So while I may yet sell too early, I won't sell until it seems I'd have given myself at least a 3- or 5-bagger, all of which would make me quite happy to have endured this currently tiring ride.
Recent DARE News
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/10/2024 08:12:44 PM
- Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024 • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 • GlobeNewswire Inc. • 04/23/2024 12:00:00 PM
- Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive • GlobeNewswire Inc. • 04/11/2024 12:00:00 PM
- Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update • GlobeNewswire Inc. • 03/28/2024 12:00:00 PM
- US Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices Rise • IH Market News • 03/28/2024 11:42:00 AM
- Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024 • GlobeNewswire Inc. • 03/21/2024 12:00:00 PM
- Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024 • GlobeNewswire Inc. • 01/31/2024 01:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 09:18:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 10:15:12 PM
- Daré Bioscience Announces Executive Team and Board of Directors Changes • GlobeNewswire Inc. • 01/26/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:30:23 PM
- Daré Bioscience Announces Grant to Support Biotherapeutic Product Development • GlobeNewswire Inc. • 01/17/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:00:38 PM
- Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 01:05:34 PM
- Daré Bioscience Secures $12 million in Royalty-backed Investment Structure • GlobeNewswire Inc. • 12/26/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 01:05:38 PM
- Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study • GlobeNewswire Inc. • 12/20/2023 01:00:00 PM
- Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study • GlobeNewswire Inc. • 12/13/2023 01:00:00 PM
- Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause • GlobeNewswire Inc. • 12/07/2023 01:00:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM